Synthes guilty pleas
This article was originally published in The Gray Sheet
Executive Summary
Former Synthes CEO Michael Huggins and the company's current Director of Clinical and Regulatory Affairs John Walsh pled guilty in a Philadelphia federal court July 20 to one misdemeanor count of shipping adulterated and misbranded Norian XR bone cement product in interstate commerce. The execs were indicted June 16 as part of a broader case against Synthes and its Norian subsidiary (1"The Gray Sheet" June 22, 2009). Huggins and Walsh could each face up to a year in prison and a $100,000 fine. They are scheduled to be sentenced Oct. 22. Two other executives, Thomas Higgins, senior VP of global strategy, and Richard Bohner, VP of operations, also were indicted and await trial, according to the Philadelphia U.S. Attorney's office
You may also be interested in...
Synthes Charged With Unauthorized Spine Repair Trial, Faces $34 Mil. Fine
Orthopedic device maker Synthes and its Norian subsidiary face $34.8 million in potential fines for allegedly skirting FDA requirements and conducting unauthorized clinical trials of their Norian XR and Norian SRS bone cement for vertebral compression fractures
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.